Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 90

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 90
---
 development or manufacturing activities with respect to any product or technology
outside of Israel. Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside of Israel
of technology or know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts that we are
required to pay to the IIA. The terms and conditions of the IIA grants may require that a company which ceases the development of know-how,
technology or products using IIA grants not due to a failure of such development activities, be required to repay such amount of grants,
which in our case, amount to $2.6 million (including interest at the amount of $0.3 million).

We may not be able to enforce covenants not-to-compete under current Israeli law that might result in added competition for our products.

We have non-competition
agreements with all of our employees and executive officers all of which are governed by Israeli law. These agreements prohibit our
employees from competing with or working for our competitors, generally during their employment and for up to 12 months after termination
of their employment. However, Israeli courts are reluctant to enforce non-compete undertakings of former employees and tend, if at all,
to enforce those provisions for relatively brief periods of time in restricted geographical areas, and only when the employee has obtained
unique value to the employer specific to that employer’s business and not just regarding the professional development of the employee.
If we are not able to enforce non-compete covenants, we may be faced with added competition.

Provisions of Israeli law may delay, prevent or otherwise impede a merger with, or an acquisition of, us, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.

Israeli
corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals
for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types
of transactions. For example, a merger may not be consummated unless at least 50 days have passed from the date on which a merger
proposal is filed by each merging company with the Israel Registrar of Companies and at least 30 days have passed from the date on
which the shareholders of both merging companies have approved the merger. In addition, a majority of each class of securities of the
target company must approve a merger. Moreover, a tender offer for all of a